Selective targeting of non-centrosomal AURKA functions through use of a targeted protein degradation tool

Richard Wang¹, Camilla Ascanelli¹, Ahmed Abdelbaki¹, Alex Fung ¹,³, Tim Rasmusson²,⁴, Iacovos Michaelides², Karen Roberts² & Catherine Lindon ¹

Targeted protein degradation tools are becoming a new therapeutic modality, allowing small molecule ligands to be reformulated as heterobifunctional molecules (PROteolysis Targeting Chimeras, PROTACs) that recruit ubiquitin ligases to targets of interest, leading to ubiquitination and destruction of the targets. Several PROTACs against targets of clinical interest have been described, but detailed descriptions of the cell biology modulated by PROTACs are missing from the literature. Here we describe the functional characterization of a PROTAC derived from AURKA inhibitor MLN8237 (alisertib). We demonstrate efficient and specific destruction of both endogenous and overexpressed AURKA by Cereblon-directed PROTACs. At the subcellular level, we find differential targeting of AURKA on the mitotic spindle compared to centrosomes. The phenotypic consequences of PROTAC treatment are therefore distinct from those mediated by alisertib, and in mitotic cells differentially regulate centrosome- and chromatin-based microtubule spindle assembly pathways. In interphase cells PROTAC-mediated clearance of non-centrosomal AURKA modulates the cytoplasmic role played by AURKA in mitochondrial dynamics, whilst the centrosomal pool is refractory to PROTAC-mediated clearance. Our results point to differential sensitivity of subcellular pools of substrate, governed by substrate conformation or localization-dependent accessibility to PROTAC action, a phenomenon not previously described for this new class of degrader compounds.
The advent of targeted protein degradation tools that exploit the endogenous protein degradation machinery to eliminate disease proteins from the cell has started a revolution in therapeutic strategy and drug design. One novel way to target proteins for degradation is through PROteolysis Targeting Chimeras (PROTACs), consisting of a chimeric molecule that binds at one end to a protein target, and at the other to a ubiquitin ligase (E3), most commonly the Cereblon (CRBN) substrate recognition protein together with the CUL4A E3 ligase complex, or to the von Hippel Lindau (VHL) protein in association with the CUL2 complex. This PROTAC-mediated ternary complex formation between functional E3 and target protein facilitates ubiquitin transfer, leading to ubiquitination of the target and its proteolysis at the 26S proteasome.

This new paradigm of “event-driven” pharmacology (in contrast to the use of traditional “occupancy-based” drugs) holds great hope for the development of catalytic drugs able to work at lower doses, and with higher specificity than the ligands from which they are derived. Moreover, the altered pharmacodynamics of substrate destruction versus inhibition raises the possibility of repurposing small molecule ligands (including those that have failed clinical trials as inhibitors of their targets) into PROTACs. However, although a number of publications document the success of novel PROTACs in eliminating their cellular targets, there has been little impact of this technology so far in the field of cell biology. PROTACs have clear potential as tools for cell biology, but this potential has been limited by the observation that the activity of PROTAC compounds can be a key determinant of PROTAC function, and that the activity of a PROTAC can be affected by the choice of E3 ligase and linker length.

We synthesized eight PROTAC molecules consisting of the E3 ligase CRBN, a known ligand for von Hippel-Lindau (VHL) E3 ligase or to the thalidomide derivative, pomalidomide, to recruit Cereblon (CRBN). As the linker is an integral part of the PROTAC molecule and linker length can be a key determinant of PROTAC function, we designed four molecules for each E3 with varying polyethylene glycol (PEG) linker lengths (Table 1, Supplementary Fig. S1).

We found that CRBN-based PROTAC compounds were able to elicit destruction of both AURKA-Venus and AURKA-VenusTO in time-lapse movies of mitotic arrested cells (Fig. 1a±d).

Compound D reduced AURKA levels in a dose dependent manner (Fig. 1b, c) with an EC_{50} in the 100 nM range (Fig. 1b). At a dose of 1 μM, Compound D caused loss of AURKA-Venus with t_{1/2} approximately 2 h (Fig. 1c). The activity of the PROTAC against AURKA-Venus in time-lapse assays (Fig. 1d), or against endogenous AURKA in extracts from mitotic arrested HeLa cells (Fig. 1e, f), appeared to correlate with linker length, suggesting that topological constraints limit the efficacy of PROTAC action. The VHL-based PROTACs tested were inactive in all but one dose (Fig. 1d). Taken together, the most efficient PROTAC tested in these initial experiments was Compound D, which we named AURKA-PROTAC-D (PROTAC-D). We tested the correlation between linker length and efficacy of the PROTAC by creating a new compound with an extra long linker, Compound DX (Table 1). As predicted, Compound DX reduced AURKA levels more efficiently than PROTAC-D (Fig. 1g). We tested the specificity of PROTAC action of CRBN-directed compounds in further experiments (Fig. 1h, i) demonstrating that neither MLN8237 nor the CRBN ligand (pomalidomide) on its own affected AURKA levels (Fig. 1h). In addition, the action of Compound D was blocked by competition with excess mitochondrial regulation.
pomalidomide (Fig. 1i), supporting that recruitment of CRBN E3 holo-complex was necessary for AURKA level reduction.

**PROTAC-mediated degradation of AURKA-Venus is independent of mitotic pathways of destruction.** While analysing these experiments, we noticed that AURKA-Venus cells arrested in mitosis with STLC were more likely to exit mitosis after treatment with PROTAC than after treatment with DMSO. As we wanted to be able to separate PROTAC treatment effects caused by target degradation from any residual inhibitory effects caused by on-target engagement, we used Compound A (Cpd A) as a negative control. Cpd A is a MLN8237-VHL molecule of
Fig. 1 AURKA destruction following treatment with CUL4-based PROTACs. a–d AURKA-VenusKI degradation in STLC-arrested RPE-1 cells, measured by quantitative timelapse imaging. Examples of fields of cells treated with a PROTAC (Compound D) or vehicle control (DMSO). Venus fluorescence was measured in individual cells and plotted as an end-point assay (percentage of AURKA-VenusKI degradation after 3 h) (b) or as percentage of AURKA-VenusKI remaining over time (to show the kinetics of degradation) (c). b Scatter plots showing response to different doses of PROTAC (Compound D) or DMSO, with whiskers indicating mean ± 5 SDs. c Time-course of AURKA-VenusKI degradation plotted as mean fluorescence ± 5 SDs at each time point (n ≥ 7 cells). d Comparison of percentage degradation of AURKA-VenusKI after treatment with potential PROTAC compounds directed to CUL4A (via CRBN) or CUL2 (VHL) ubiquitin ligases (listed in Table 1). Scatter plots show pooled results from two separate experimental repeats with whiskers indicating mean ± SDs. Results of Kruskal-Wallis multiple ANOVA, and the Dunn’s post-hoc multiple comparison test to DMSO are indicated. e, f Degradation of endogenous AURKA in HeLa cells following 3 h treatment with PROTACs, with or without 42 μM proteasome inhibitor MG132, measured by quantitative immunoblotting (e) to plot percentage protein remaining, ordered to show increasing linker size across the series (f). g U2OS and HeLa cells were treated for 3 h with 250 nM Compound D (PROTAC-D) or a new compound with increased linker length (PROTAC-DX). Endogenous AURKA levels were measured by immunoblot and plotted as remaining percentage compared to DMSO treatment after normalization to GAPDH loading control. The experiment shown is one of two repeats that gave identical results. h Degradation of AURKA-VenusKI was measured in prometaphase cells treated with 1 μM PROTAC-D, MLN8237, or pomalidomide. Scatter plots showing response to different doses of PROTAC (Compound D) or new compound with increased linker length (PROTAC-DX) are shown in Fig. 1c. i As a control, we asked whether target destruction mediated by PROTAC-D was specific to AURKA. Since the PROTAC target ligand MLN8237 has a degree of selectivity for AURKA over its cellular parologue AURKB, but is not completely specific (it inhibits AURKB activity at doses of ≥50 nM), and the reported selectivity ratio AURKA:TPX2 (1:43), AURKB:INCENP (783:918) is approximately 5-fold, we might expect to find some degradation of AURKB in response to a PROTAC carrying the MLN8237 warhead.

**Table 1** Summary of compounds tested.

| Cpd | Substrate ligand ("warhead") | E3 ligand target | Linker length (M) |
|-----|-------------------------------|-----------------|------------------|
| A   | MLN8237 (alisertib)           | VHL             | 288              |
| B   | MLN8237                       | CRBN            | 272              |
| C   | MLN8237                       | VHL             | 200              |
| D   | MLN8237                       | CRBN            | 316              |
| DX  | MLN8237                       | CRBN            | 404              |
| E   | MLN8237                       | VHL             | 244              |
| F   | MLN8237                       | CRBN            | 222              |
| G   | MLN8237                       | VHL             | 156              |
| H   | MLN8237                       | CRBN            | 184              |

* M, relative molecular weight.

identical linker length to PROTAC-D that did not cause degradation of AURKA (Fig. 1d). It had a small and non-significant effect in promoting mitotic slippage compared to PROTAC-D (Fig. 2a). Since AURKA is itself a substrate of mitotic exit degradation under control of the APC/C<sup>27</sup>, failure of the SAC, leading to activation of the APC/C, would be predicted to result in degradation of AURKA independently of PROTAC-mediated ubiquitination. Therefore, in the single cell mitotic degradation assays shown in Fig. 1, we quantified only cells that remained arrested in mitosis for the duration of the assay. However, we also carried out experiments to test directly whether mitotic degradation pathways were involved in PROTAC-D-driven disappearance of AURKA-Venus using a combination of drugs (APCin, proTAME), that inhibits the activity of the APC/C ubiquitin ligase<sup>26</sup>. Degradation of AURKA-Venus in response to PROTAC-D was not prevented by inhibition of APC/C (Fig. 2b, c) and was therefore independent of mitotic exit.

The effect of PROTAC-D in promoting mitotic exit could potentially be explained by a number of studies showing a role for AURKA in the SAC<sup>27-29</sup>, but could also occur through “mitotic slippage”, should there be any non-specific targeting of Cyclin B1 by PROTAC-D in the presence of an active SAC<sup>30</sup>. We tested this possibility using a RPE1-cyclin B1-Venus<sup>K1</sup> line<sup>51</sup>. Degradation of Cyclin B1-Venus and escape of cells from SAC-induced arrest were both strongly promoted by PROTAC-D (Fig. 2d, e, and weakly by Cpd A. However, in contrast to AURKA-Venus<sup>K1</sup> degradation (Fig. 2b), Cyclin B1-Venus<sup>K1</sup> degradation measured upon PROTAC-D treatment was sensitive to APC/C inhibition (Fig. 2f). These results allowed us to conclude that Cyclin B1-Venus degradation in the presence of PROTAC-D is the result of a weakened SAC and that Cyclin B1 is not targeted directly by PROTAC-D.

In further experiments to test that degradation of AURKA in response to PROTAC-D was independent of the well-characterized APC/C-dependent pathway, we used versions of AURKA known to be resistant to APC/C-mediated degradation. AURKA possesses an atypical APC/C degron motif, the so-called A-box, in its N-terminal disordered region<sup>32</sup>. The A-box function appears to be negatively regulated through phosphorylation on Ser51, since phospho-mimic substitution (S51D) at this site blocks mitotic degradation of AURKA<sup>33,34</sup>. We found, using single cell time-lapse degradation assays, that an A-box deleted (A32-66) version of AURKA-Venus stably expressed in an RPE-FRT/TO line was efficiently degraded in response to PROTAC-D (Fig. 2g). We concluded that PROTAC-mediated degradation of AURKA does not require the substrate motif essential for its canonical degradation, either for ubiquitination, or at any downstream step in substrate processing at the 26S proteasome. We additionally tested the S51D version of AURKA-Venus alongside the WT protein in time-lapse degradation assays, after transient transfection into U2OS cells. We found not only that both WT and “non-degradable” S51D were sensitive to PROTAC-D in mitotic cells (Fig. 2h), but that they were also sensitive in interphase cells (Fig. 2i), as further confirmation that PROTAC-mediated processing of AURKA for destruction is independent of cell cycle-dependent pathways. We note that the measured rate of degradation is lower in interphase cells than mitotic cells, most likely because degradation is masked by ongoing synthesis (observed as accumulation of the protein in DMSO-treated control cells). We concluded that degradation of AURKA measured in response to PROTAC-D treatment is a direct consequence of PROTAC-D-mediated targeting. Furthermore, since some experiments were carried out using high-level transient expression of transfected constructs (Fig. 2h, i), PROTAC-D appears potent enough to clear target protein at significant levels of overexpression in the cell.

PROTAC-D action is highly selective for AURKA. Next, we asked whether target destruction mediated by PROTAC-D was specific for AURKA. Since the PROTAC target ligand MLN8237 has a degree of selectivity for AURKA over its cellular parologue AURKB, but is not completely specific (it inhibits AURKB activity at doses of ≥50 nM<sup>3</sup>, and the reported selectivity ratio AURKA:TPX2 (1:43), AURKB:INCENP (783:918) is approximately 5-fold<sup>5</sup>, we might expect to find some degradation of AURKB in response to a PROTAC carrying the MLN8237 warhead.
Fig. 2 CUL4-mediated AURKA destruction is independent of known pathways of AURKA degradation. **a** RPE1-AURKA-VenusΔKI cells treated as in Fig. 1d were scored for mitotic slippage (exit from mitosis in presence of STLC). Percentage of cells undergoing slippage after 3 h treatment with PROTAC-D or Cpd A is shown relative to DMSO-treated cells. Mean values were generated from three identical experiments (where \( n \geq 30 \) cells), plotted with error bars to indicate SDs and tested by ordinary one-way ANOVA with Dunnett’s post-hoc test for significance. **b**, **c** Degradation of AURKA-Venus in mitotic-arrested RPE1-AURKA-VenusΔKI cells after treatment with PROTAC-D in the presence of APCin/proTAME. Degradation was measured in single cell assays, with data shown as scatter plots (bars to indicate means ± SDs) tested with unpaired t-Test or Mann–Whitney U-test for significance (**b**) or visualized as a time-course of drug treatment by immunoblot (**c**). **d**–f RPE1-Cyclin B1-VenusΔKI cells treated with PROTACs to investigate mitotic slippage. Increased degradation of Cyclin B1-Venus following PROTAC-D treatment (**d**), correlates with increased rate of mitotic exit (**e**) (both results statistically tested by ordinary one-way ANOVA with Dunnett’s post-hoc test for significance) and is blocked by co-treatment with APC/C inhibitors APCin (40 µM) and proTAME (20 µM) (unpaired t-Test or Mann–Whitney U-test for significance) (**f**). **g**–i “Non-degradable” AURKA-Venus is degraded efficiently in response to PROTAC-D: AURKA-Venus-Δ32-66 (ΔA-box) expressed in RPE1 cells (tet-inducible RPE1-FRT/TO pool) is sensitive to PROTAC-D (unpaired t-test for significance) (**g**). WT or Ser51D versions of AURKA-Venus transiently electroporated into U2OS cells are equally sensitive to PROTAC-D treatment in either mitotic cells arrested by STLC (**h**) or interphase cells (**i**) (unpaired t-test or Mann–Whitney U-test for significance). Ongoing protein synthesis is likely to mask the degradation rate of Venus-tagged protein in interphase cells.
Furthermore, considering that within the mitotic cell AURKA resides in multiprotein complexes governing its localization and function, we hypothesized that the "ectopic" recruitment of ubiquitination machinery by PROTAC-D might lead to ubiquitination and destruction of AURKA binding partners. Therefore, we examined if PROTAC-D caused a reduction in cellular levels of AURKB, or of two well-known interacting partners of AURKA, TPX2 and TACC3 (Fig. 3).

Surprisingly, we found that treatment with PROTAC-D caused very little degradation of AURKB-Venus in an inducible U2OS cell line (Fig. 3a), or of endogenous AURKB in HeLa cells (Fig. 3b, c). We also found no degradation of endogenous TPX2 in mitotically-enriched HeLa cells after 3 h of treatment with PROTAC-D (Fig. 3b, c). TPX2 and TACC3 levels were unchanged in cells treated for up to 12 h, when endogenous AURKA was no longer detectable (Fig. 3d). Therefore PROTAC-D-mediated destruction is highly specific for AURKA. The stability of AURKA binding partners in presence of PROTAC-D suggests that the ubiquitination step is selective for the AURKA moiety of mitotic complexes, or alternatively, that only unbound AURKA is targetable by PROTAC-D.

Given the unexpected resistance of AURKB to AURKA PROTAC action, we compared in vitro kinase inhibition activities for AURKA and AURKB of PROTACs –D and –DX, Cpd A, and their warhead MLN8237. We found that both of the PROTACs had greater selectivity for AURKA over AURKB than MLN8237 in kinase inhibition assays (fold selectivity of PROTAC-D = 21.6, PROTAC-DX = 23.7, MLN8237 ≥ 8.3) (Table 2), consistent with the lack of AURKB degradation seen in Fig. 3a–c. Increased selectivity for AURKA suggests that the increased size and/or complexity of the PROTAC creates new steric parameters influencing target discrimination, and is consistent with published findings from others that the requirement for ternary complex formation in PROTAC action can build a further layer of specificity into drug action.

Comparing IC_{50} values for inhibition of in vitro kinase activity of PROTAC-D and PROTAC-DX versus MLN8237, we found that inhibition of AURKA kinase activity by the PROTAC molecules is weaker than that mediated by MLN8237 (5–10-fold). Interestingly PROTAC-DX, which has stronger PROTAC activity in comparison to PROTAC-D (Fig. 1g), does not have higher activity in this assay (Table 2, Supplementary Fig. S2). This finding is in line with the idea that the efficiency of PROTAC activity is not only impacted by binding affinity to the target or E3 ligase, but also related to efficiency of ternary complex formation between E3 and target protein.

Centrosome-localized AURKA is not sensitive to PROTAC-D. Having validated PROTAC-D as an effective and specific tool for depletion of cellular AURKA, we investigated how PROTAC-
mediated AURKA destruction would compare to enzymatic inhibition as a method for down-regulating AURKA functions in mitotic cells. We fixed cell populations synchronized for passage through mitosis and treated for 4 h with parallel doses of PROTAC-D or MLN8237, or with DMSO as a negative control, and stained them by immunofluorescence (IF) for the presence of AURKA, markers of AURKA activity and tubulin, in order to assess the phenotypic consequences of treatment with different compounds (Fig. 4). We looked first at AURKA staining and found that cells treated with PROTAC-D displayed a marked loss of the pool of AURKA associated with the spindle (seen in DMSO-treated controls). However, AURKA was preserved at the centrosomes (Fig. 4a). By contrast, treatment with MLN8237 abrogated almost all AURKA localization to centrosomes, consistent with the known role of AURKA activity in centrosome maturation that includes recruitment of AURKA to the pericentriolar material (PCM)\(^{38}\). This finding suggested that the centrosome-associated pool of AURKA seen in PROTAC-D-treated mitotic cells would be unexpectedly active (that is, neither degraded nor inhibited by PROTAC treatment). We tested this idea by measuring levels of pSer3-LATS2 as a well-known centrosomal marker of AURKA activity, finding that this marker was entirely resistant to PROTAC-D treatment (at doses sufficient to deplete most of the cellular pool of AURKA), whilst responding in dose-dependent fashion to MLN8237 (Fig. 4b, c).

Given the >5-fold difference in enzyme inhibition of PROTAC-D and MLN8237 (Table 2) and the likelihood that the intracellular dose of PROTAC-D is limited by its size and solubility, we examined the phenotypic consequences of treatment over a 10-fold range of doses of both compounds, scoring mitotic figures according to the categories illustrated in Supplementary Fig. S3. Dose-response to MLN8237 treatment is characterized by progression from spindle orientation defects at low doses to spindle assembly defects (multipolar spindles, “small” spindles) at intermediate doses, to lack of MT nucleation at a dose of 250 nM (Fig. 4d and as previously described\(^{4}\)). We were surprised to find that PROTAC-D-treated cells showed none of these defects (Fig. 4d, e). Even at the highest dose tested (250 nM), we did not see the orientation defects characteristic of low dose inhibition of AURKA activity\(^{4,39}\). Instead, we observed that the mitotic spindles were shorter in length after PROTAC treatment. Distribution of the centrosomal pLATS2 staining shown in Fig. 4b confirms that the pole-to-pole distance of correctly oriented bipolar spindles is reduced (Fig. 4f).

PROTAC-D and MLN8237 mediate distinct effects in mitotic cells. Our finding of “short spindles” was reminiscent of the previously reported finding that specific perturbation of AURKA binding to TPX2 controls spindle length independently of any effect on assembly\(^{33}\), which can occur under the influence of the centrosomal AURKA pool. Therefore, we hypothesized that PROTAC-D had selectively depleted the TPX2-associated pool of AURKA to eliminate the chromosome-centered MT nucleation pathway whilst leaving the centrosomal pathway untouched. We decided to test this idea using a modified cell synchronization assay that would better allow us to compare the roles of kinase inhibition and target degradation in mitotic cells independent of their different effects on AURKA-dependent centrosome maturation. We pre-synchronized cells at metaphase by release of cells arrested for 24 h in Thymidine into APcin/proTAME for 6 h. We then treated metaphase-arrested cells with different doses of MLN8237, PROTAC-D and Cpd A for 3 h before fixing them for IF analysis. We first examined the pT1288 epitope as a direct readout for inhibition of AURKA, finding as expected that PROTAC-D and Cpd A show weaker inhibition of AURKA activity than MLN8237. Importantly, the extent of inhibition by PROTAC-D and Cpd A is similar, confirming that both are able to access the centrosomal pool of AURKA (Fig. 5a, b) and enabling us to reason that comparing the effects of these compounds would reveal phenotypes arising from degradation of AURKA, distinct from those arising purely due to kinase inhibition.

Next, we stained cells for AURKA and its interactors CEP192 and TPX2 (Fig. 5c–h). Similar levels of CEP192 at centrosomes after the different treatments confirmed that centrosome maturation had occurred in a large fraction of the cellular pool of metaphase cells (Fig. 5c). Quantification of AURKA levels in these cells showed the total cellular pool of AURKA reduced more than three-fold after PROTAC-D treatment (Fig. 5d). Measured AURKA levels were also somewhat lower (by about 30%) after treatment with Cpd A or with low (25 nM) or high (250 nM) doses of MLN8237. Since we have found that these treatments do not affect endogenous AURKA levels, nor AURKA-Venus levels in intact cells, we assumed that the reduced AURKA levels seen in IF reflected loss of AURKA in the fixation step, that could be a consequence of reduced interaction with the mitotic spindle. Indeed, MLN8237 and TPX2 may compete with each other for AURKA binding\(^{40}\) (see “Discussion” section). We measured pole-pole distances in this experiment and found them reduced by PROTAC-D treatment. AURKA inhibition with 25 nM MLN8237 also gave rise to short spindles, whereas Cpd A had no effect on spindle length (Fig. 5e). We concluded that Cpd A and PROTAC-D both bind too weakly to AURKA to significantly inhibit its activity, and that the short spindle phenotype seen after PROTAC-D treatment depends on destruction of AURKA by PROTAC-D. Consistent with this conclusion, we observed that PROTAC-D alone of the three treatments removed both cytoplasmic and spindle pools of AURKA (Fig. 5f). Kinase inhibition mediated by 25 nM MLN8237 or 250 nM Cpd A caused some loss of signal from the spindle, but also increased cytoplasmic levels of AURKA (Fig. 5f, g). Comparison of AURKA pixel intensities in fixed areas on the centrosome or neighboring spindle confirmed that depletion of the spindle signal was greater than at the centrosome (Fig. 5h). We concluded from our data that PROTAC-D preferentially depletes the pool of AURKA that associates with TPX2 to govern mitotic spindle length. Moreover, because kinase inhibition assays indicate that Cpd A and PROTAC-D bind AURKA with equivalent affinity (Fig. 5b and Table 2), we concluded that the short spindle phenotype seen after PROTAC-D—but not Cpd A—treatment (Fig. 5e) depends on destruction of AURKA protein.

### Table 2 Affinity and selectivity of compounds for AURKA.

| Cpd          | IC\(_{50}\) (nM) | Fold-selectivity |
|--------------|-----------------|-----------------|
| MLN8237 (alisertib) | 0.63 | 5.25 | ≥8.3\(^{a}\) |
| PROTAC-D     | 3.58 | 77.2 | 21.6 |
| PROTAC-DX    | 4.78 | 113  | 23.7 |
| CpdA         | 6.17 | 95.4 | 15.5 |

*Measured IC\(_{50}\) for AURKA is at the lower limit of dose range and below the theoretical tight binding limit of the assay. Therefore true IC\(_{50}\) may be somewhat lower (and fold-selectivity higher).*

We investigated further why PROTAC-D treatment led to selective depletion of distinct target pools by PROTAC-D. We aimed to identify the reason why PROTAC-D treatment led to selective depletion of the spindle-associated pool of AURKA, hypothesizing that this could be a consequence of conformation-dependent targeting by the PROTAC, with the preferred target...
being either the TPX2-bound pool or a free pool of AURKA (provided this turns over faster with the TPX2-bound pool than the centrosomal pool). We tested this idea by using conformational mutants of AURKA-Venus. AURKA-S155R is a version of AURKA showing reduced interaction with TPX2 (and therefore weak localization to the mitotic spindle), whilst its centrosomal localization is maintained. The non-catalytic N-terminal IDR of AURKA is known to mediate interaction with a number of binding partners, so N-terminally truncated versions of AURKA, 68–403 (Δ67) and 128–403 (Δ127), are predicted to show reduced interactions with binding partners, including a potential auto-inhibitory interaction with the kinase domain.

---

**Fig. 4 AURKA remains active at centrosomes upon PROTAC treatment.**

a–c Immunofluorescence analyses of U2OS cells synchronized through mitosis and treated for 3 h with MLN8237, PROTAC-D, or DMSO vehicle control. AURKA staining is retained at the centrosomes after PROTAC-D treatment (a) whilst a marker for active AURKA at centrosomes, p(Ser83)LATS2, persists after PROTAC-D treatment but not MLN8237 treatment (b, c).

c Measurement of centrosomal pLATS2 staining from immunofluorescence images after cytoplasmic background subtraction (Kruskal–Wallis multiple ANOVA, and Dunn’s post-hoc multiple comparison test to DMSO for significance). d, e Mitotic phenotypes scored from TPX2/DAPI staining of fixed cells (categories illustrated in Supplementary Fig. S3). d Dose-dependence of phenotypes using pooled data from three coverslips for each condition from a single experiment. e Mitotic categories scored at a single dose (100 nM), using data from two coverslips each from three independent repeats of the experiment, mean values ± SDs for each experiment are plotted. f Line-scans through fixed mitotic cells stained with pLATS2 (as shown in b), to show both poles of the spindle (visible as maxima of staining intensity), reveal reduced pole–pole distance after PROTAC-D treatment. Traces show mean values from n ≥ 22 individual mitotic spindles, with fainter traces above and below representing SDs.
We found that in RO3306-arrested interphase cells, overexpressed S155R and wild-type versions of AURKA-Venus showed a similar pattern of targeting by PROTAC-D. However, in cells arrested in prometaphase with STLC, where TPX2 is a major binding partner of AURKA, S155R was more rapidly degraded than the wild-type, consistent with the idea that PROTAC-D preferentially depletes free AURKA in mitotic cells (Fig. 6a). The N-terminally truncated version of AURKA Δ127 was insensitive to PROTAC-D, and in the absence of PROTAC treatment accumulated strongly (Supplementary Fig. S4) and we concluded that it probably lacks substrate lysines and/or IDR required for ubiquitination or processing at the 26S proteasome. The Δ67 version of AURKA-Venus was, however, more sensitive to PROTAC-D than the full-length protein under all conditions tested (Fig. 6b, and Supplementary Fig. S4). This finding is consistent with the idea that interactions mediated through the N-terminal IDR impede PROTAC-D-mediated degradation of the target.

In order to confirm that subcellular pools of wild-type AURKA also showed differential sensitivity to PROTAC-D, we experimented instead on RPE1-AURKA-VenusK1 cells treated with siRNA against CEP192 (CEP192i) to displace AURKA from the centrosomes19. Displacement of AURKA-Venus was readily observed in cells arrested in G2 phase with RO3306, when AURKA-VenusK1 expression is high (Fig. 6d, quantified in Supplementary Fig. S5). We tested AURKA-Venus degradation in response to PROTACs under these conditions and measured slightly increased degradation of AURKA-Venus in single cells or by immunoblot (Supplementary Fig. S5). We then tested the effect of CEP192i on mitotic cells, when a much larger pool of AURKA is normally recruited to centrosomes. In STLC-arrested cells we found that AURKA-VenusK1 delocalized from centrosomes after CEP192i (Fig. 6e, f) was more readily degraded in response to PROTAC-D (Fig. 6g). We concluded that the centrosome localized pool of AURKA-Venus shows reduced sensitivity to PROTAC-D.

**Inhibition of cytoplasmic AURKA activity by PROTAC-D.**

Recent studies of AURKA have highlighted that interphase functions may contribute to its tumorigenic activity. One interphase function is regulation of the mitochondrial network and our recent work has shown that excess AURKA present in interphase FZR1KO cells causes fragmentation of the mitochondrial network24. This activity of AURKA, promoted through stabilization of the protein, represents an interesting context for testing PROTAC strategies, so we tested the action of PROTAC-DX on mitochondrial fragmentation in FZR1KO cells. We treated FZR1KO cells with PROTAC-DX and Cpd A and found that PROTAC-DX, but not Cpd A, restores mitochondrial morphology (Fig. 7a, b). Therefore PROTAC-DX is able to prevent interphase activity of AURKA in a manner that depends on destruction of the protein. We conclude that PROTAC-mediated clearance is an efficient strategy for downregulating excess AURKA activity in interphase cells.

**Discussion**

We have described a small molecule that acts as a specific degrader of AURKA to clear endogenous, exogenous GFP-tagged, or overexpressed protein from the cell. Amongst the molecules we tested, successful degraders were CRBN-specific. Although, we have not formally excluded the possibilities that VHL is insufficiently active in U2OS cells to generate degradation-competent ubiquitin conjugates in response to Cpd A, or that the four linker constructs we tested all occluded ternary complex formation between AURKA and VHL, our observation that the same four linker constructs were all able to support PROTAC activity directed to CRBN are in line with the published finding that protein–protein interaction surfaces of CRBN are more favorable to stable ternary complex formation than the equivalent surfaces of VHL. As widely reported in the literature, PROTACs have poor solubility and cell permeability. Therefore we also considered the possibility that our VHL-directed compounds are less cell permeable than their CRBN-directed matching compounds, by testing our VHL-directed “control” compound, Cpd A, for its ability to inhibit AURKA activity both in cells as well as in vitro. We found that PROTAC-D and Cpd A showed similar activity in both assays (Fig. 5a and Table 2).

Compounds showing PROTAC activity against AURKA were several-fold less potent than their MLN8237 warhead in inhibiting AURKA activity in vitro, consistent with reduced affinity for their target. Indeed, we found that the partial inhibition of AURKA activity in response to PROTAC-D treatment (pT288-AURKA staining, Fig. 5) was insufficient to reduce AURKA function at the centrosomes (pS83-LATS2 staining, Fig. 4), and that non-centrosomal AURKA was insensitive to Cpd A inhibition (since mitotic spindle assembly was unaffected). Therefore we concluded that binding of PROTAC-D is weak enough, and/or the molecule present at sufficiently low intracellular levels, to achieve targeted degradation of AURKA in absence of functional consequences to the inhibition of AURKA kinase activity, and without exhibiting the hook effect characteristic of heterobifunctional ligands. The question of the intracellular effective dosage of PROTACs remains an elusive parameter.
We found that the activity of CRBN-directed molecules correlated with linker length but was independent of the affinity of the compound for its AURKA target. Therefore, it is likely that our longer linkers promote the assembly of productive ternary complexes by bringing together AURKA and CRBN in an orientation that allows the E3 complex to ubiquitinate AURKA at appropriate lysine residues. The physical properties of the linker are critical parameters in PROTAC activity, and further optimization of PROTAC-DX could include different linker patterns to alter linker flexibility, as well as lengths.

We observed that clearance of wild-type AURKA from the cell is less efficient than that mediated by its cognate E3, APC/C-FZR1 ($t_{1/2} \approx 100$ min vs. $t_{1/2} \approx 45$ min$^{18}$). We speculate that even with further optimization, it seems unlikely that any PROTAC would eliminate AURKA faster than its cognate pathway, since the rate-limiting step for degradation of many ubiquitinated substrates is not recruitment to the 26S proteasome, but determinants of processing that are partly substrate-specific (such as unfolding of substrate at the proteasome) and partly determined by the configuration of ubiquitin chains$^{17}$. Indeed, a recent study
found that the presence of unstructured regions determines the PROTAC mediated degradation of VHL-directed substrates. However, we found that PROTAC-D could clear versions of AURKA resistant to APC/C-mediated degradation (through mutation or removal of the essential N-terminal degron) as efficiently or better than the wild-type AURKA. We conclude from this that the position and topology of ubiquitin chains assembled on AURKA by CUL4A-CRBN and APC/C-FZR1 are likely to be very different, and that PROTACs are promising tools for targeting mutant versions of cellular proteins that have acquired resistance to canonical degradation pathways.

We also observed that different cellular pools of AURKA substrate were differentially targeted by PROTAC treatment, since in mitotic cells the spindle-associated fraction of AURKA was eliminated whilst the centrosome fraction was preserved (Fig. 8). Since the centrosomal pool of AURKA retained its activity, spindle assembly was buffered against the loss of the chromatin-associated TPX2-activated AURKA pool and the observed phenotype of PROTAC-D treatment in mitotic cells is therefore shortened spindles, consistent with a previous study of cells engineered to express a non-AURKA-binding version of TPX2. Similarly, in interphase cells we observed that PROTAC-D treatment efficiently cleared the non-centrosomal pool of AURKA, but that centrosomal AURKA was preserved. Delocalization of the centrosomal pool through siRNA-mediated depletion of CEP192 promoted clearance of the total cellular pool of AURKA-Venus by PROTAC-D. Since centrosomal AURKA is efficiently inhibited by MLN8237, we would expect it to be accessible to bind MLN8237-derived PROTAC molecules. One explanation for its inaccessibility to PROTAC-D action

Fig. 7 PROTAC-D treatment restores the mitochondrial network in FZR1KO cells. U2OS FZR1KO cells, in which mitochondria are highly fragmented due to the presence of excess AURKA, were treated for 3 h with DMSO or with MLN8237, Cpd A or PROTAC-D at the doses indicated. Cells were then stained with MitoTracker Red, imaged and analysed for mitochondrial fragment lengths as described in materials and methods. a Representative images of cells analysed. Scalebar, 10 μm. b Scatter plots showing mean mitochondrial fragment lengths, mean and SDs under different drug treatments. Each datapoint represents the mean value from 30 mitochondria per cell, n ≥ 12 cells, with results tested for significance using Mann–Whitney U-test. The data are from a single experiment that is representative of two identical repeats of the same experiment.

Fig. 8 Targeting of non-centrosomal AURKA functions by PROTAC-D. Schematic to illustrate the distinct actions of MLN8237 and PROTAC-D on AURKA pools in mitotic cells. Both centrosomal and spindle pools of AURKA are inhibitable by MLN8237, whereas PROTAC-D clears the spindle pool of AURKA whilst leaving active AURKA at the centrosome. Figure made in ©BioRender (biorender.com).
could be that centrosomal localization, or the interaction with CEP192, block recruitment of CRBN or another component of the E3 complex required for ubiquitination of its target. Alternatively, there may be deubiquitinase enzymes active at the centrosomes that act to stabilize ubiquitinated AURKA.

Our results point to differential accessibility of subcellular pools of substrate, governed by substrate conformation, binding partners, or localization in compartments more or less accessible to PROTAC action, a phenomenon that has not previously been described for PROTAC agents acting via CRBN. Our finding of localized response to PROTAC-D is in contrast with treatment by the AURKA inhibitor alisertib, which promotes a clear dose-dependent depletion of pLAT52, a marker of AURKA activity at the centrosomes.

Given the complex conformational and spatial regulation of AURKA, we tested for conformation-specific targeting of the kinase using different versions of AURKA-Venus. The conformational dynamics of AURKA are strongly constrained through interaction with TPX240,49,50, which favors the so-called "DFG-In" active conformation. A recent study from the Levinson group suggested that different functional pools of the kinase display distinct conformational properties that modulate interactions with inhibitors, with alisertib/MLN8237 shown to be a "Type 1" inhibitor that promotes the inactive DFG-Out state, and TPX2 shown to oppose DFG-Out inducers, exhibiting negative cooperativity on binding with MLN8237. In the DFG-Out state, the active site is more open (i.e., more accessible to MLN8237 or other components required for efficient ubiquitination in response to PROTAC-D. We tested this idea with truncation of the non-catalytic domain of AURKA to reduce interaction with some binding partners, whilst not affecting the ability of PROTAC-D to access the catalytic domain. Δ67 was degraded more efficiently than the full-length protein under all conditions tested, consistent with the idea that binding partners influence the ability of PROTAC-D to bring about degradation of its target.

AURKA is of strong interest as a therapeutic target for various cancers, but despite extensive testing in clinical trials, alisertib has yet to reach the clinic. Our study is the first to describe a degrader compound that shows specificity for different subcellular pools of AURKA, raising the possibility of developing PROTACs to fine-tune the activity of AURKA (and other targets that have shown disappointing clinical results) to produce cellular phenotypes that are potentially more desirable in pharmacological or therapeutic contexts. For example, alisertib-derived PROTACs could be used to target cytoplasmic functions of AURKA without inducing mitotic errors that are the consequence of inhibiting AURKA function at the centrosome.

For assaying live cell degradation of AURKA-VenusT20 in G2 arrested cells, 1.5 × 106 RPE1 AURKA-T20 cells were seeded per well in 8-well slides (Ibidi GmbH) and treated for 16 h with 10 μM S-trityl l-cysteine (STLC) (Tocris Bioscience) prior to PROTAC treatment.

**Methods**

**Cell culture and synchronization.** U2OS and HeLa cells were cultured in DMEM (Thermo Fisher Scientific) and hTERT-RPE-1 cells in DMEM/F12 mix, supplemented with 10% FBS, 200 μM Glutamax-1, 100 U/mL penicillin, 100 μg/mL streptomycin, and 250 μg/mL fungizone. All cells were grown in humidified atmosphere at 37 °C with 5% CO2. RPE-1 AURKAΔ23 cells, RPE-1 AURKATO cells, Tet-Off cell lines U2OS-AURKA-Venus and U2OS-AURKB-Venus, have all been previously described25,51.

For assaying live cell degradation of AURKA-VenusT20 and AURKA-VenusT20 in mitotic arrested cells, 1.5 × 106 RPE1 AURKA-VenusΔ23 cells were seeded per well in 8-well slides (Ibidi GmbH) and treated for 16 h with 10 μM S-trityl l-cysteine (STLC) (Tocris Bioscience) prior to PROTAC treatment.

**Drug treatments.** AURKA PROTACs and pomalidomide were synthesized in-house and used at ≤1 μM. Detailed chemical synthesis of Compounds A–H is described in Supplementary Methods. Aurora A kinase inhibitor MLN8237 (Stratche, Ely, UK) was used at ≤1 μM, MG132 (Alfa Aesar) at 42 μM, R30306 (Tocris Bioscience) at 10 μM, AP2Cm (Bio Technne) at 20 μM and ProTame (R&D Systems) at 40 μM.

**Cell transfection.** Cells were transfected with 1 μg of plasmids using Neon Transfection System (Thermo Fisher Scientific) using the following parameters: pulse voltage 150 V; pulse width 10 ms, and two pulses total on the transfection device according to the manufacturer's protocol. AURKA and AURKB plasmids were used expressed with C-terminal Venus tags in pVENUS-N1 vector. Δ32–66, 551Δ, S155R, Δ67, and Δ127 versions of AURKA were generated by mutagenesis, with clones available on request.

CPE192 knockdown was achieved by transfecting the oligo duplex: 5’-GGAGAACAUUUUCAAUCUCU-3’ and 5’-AGAGAAUGAAGAAUGUCCU-3’ (Sigma).

**Immunoblotting.** Cell extracts were prepared in NuPage (Invitrogen) SDS sample buffer with 100 μM DTT. Extracts were syringed and boiled prior to electrophoresis on NuPage precast 4–12% Bis–Tris SDS-PAGE gels (90 mm, 150 V, 80 W). Proteins were transferred on to Immobilon-FL PVDF (Millipore), and membranes were exposed to MitoTracker Red CMXRos (Thermo Fisher Scientific) as per manufacturer’s instructions.
Secondary antibodies used were: Alexa Fluor 488 anti-mouse and Alexa Fluor 568 anti-rabbit (Thermo Fisher Scientific).

Microscopy. All images were acquired on automated epifluorescence imaging platforms based on Olympus IX81 or IX83 inverted microscopes (Olympus Life Science, Southend-on-Sea, UK) with LED illumination source and motorized stage. Time-lapse was carried out using cells seeded on ibidi 8-well slides, and imaged at 37°C in L-15 medium/10% FBS using a 40× NA1.3 OIL objective. Epifluorescent stacks of fixed cells after processing by IF were acquired using 60× NA 1.4 OIL objective with 200 nm step. Image acquisition was controlled by Micro-Manager53 and images exported as tiff files.

Image analysis and quantifications. Images were analysed using FIJI44, measuring net green intensity (I) of cell after background subtraction at T0 and T200 min. Picked cells which remained in prometaphase for the duration of the 200 min% degradation measured as (T0−T200)/T0. Linescans were carried out using the BAR package in FIJI. Mitochondrial lengths were analysed using MicroP55.

AURKA and AURKB biochemical assays. AURKA and AURKB biochemical assays were performed as part of the ThermoFisher SelectScreen™ kinase profiling service (see full experimental protocol in Supplementary Information). Compounds were tested in AURKA or AURKB Z'LYTE kinase assays using full-length purified protein (3 nM for AURKA, 20 nM for AURKB) and ATP at Km (10 μM for AURKA, 75 μM for AURKB). Across the three replicate assays, the assay Z' averaged 0.87 for AURKA and 0.84 for AURKB.

Statistics and reproducibility. The number of biological repeats (two, three, or four) for all experiments are indicated in figure legends. For live cell experiments data are presented either as mean values ± SDs from biological repeats, or pooled raw data as indicated in figure legends. For immunofluorescence analyses, two or three cover-slips were prepared for each condition as technical repeats, with data averaged 0.87 for AURKA and 0.84 for AURKB.

Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

The authors declare that all data supporting the findings of this study are available within the paper and its Supplementary Information files. 1H and 13C NMR and HRMS analyses of the compounds described in this study are shown in the Supplementary Methods file. Quantified data are assembled are available in Supplementary Data 1 file.

Received: 22 July 2020; Accepted: 29 April 2021;
Published online: 28 May 2021

References

1. Hanzl, A. & Winter, G. E. Targeted protein degradation: current and future challenges. Curr. Opin. Chem. Biol. 56, 35–41 (2020).
2. Bondeson, D. P. et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat. Chem. Biol. 11, 611–617 (2015).
3. Winter, G. E. et al. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348, 1376–1381 (2015).
4. Asteriti, I. A. et al. The Aurora-A inhibitor MLN8237 affects multiple mitotic processes and induces dose-dependent mitotic abnormalities and aneuploidy. Oncotarget 5, 6229–6242 (2014).
5. Manfredi, M. G. et al. Characterization of alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacokinetic-metabolism models. Clin. Cancer Res. 17, 7614–7624 (2011).
6. de Groot, C. O. et al. A cell biologist’s field guide to aurora kinase inhibitors. Front. Oncol. 5, 285 (2015).
7. Barr, A. R. & Gergely, F. Aurora-A: the maker and breaker of spindles. J. Cell Sci. 120, 2987–2996 (2007).
8. Prosser, S. L. & Pelletier, L. Mitotic spindle assembly in animal cells: a fine balancing act. Nat. Rev. Mol. Cell Biol. 18, 187–201 (2017).
9. Kufer, T. A. et al. Human TPX2 is required for targeting Aurora-A kinase to the spindle. J. Cell Biol. 158, 617–623 (2002).
10. Joukov, V., De Nicolao, A., Rodriguez, A., Walter, J. C. & Livingston, D. M. Centrosomal protein of 192 kDa (Cep192) promotes centrosome-driven assembly by engaging in organell-specific Aurora A activation. Proc. Natl Acad. Sci. USA 107, 21022–21027 (2010).
11. Bird, A. W. & Hyman, A. A. Building a spindle of the correct length in human cells requires the interaction between TPX2 and Aurora A. J. Cell Biol. 182, 289–300 (2008).
12. Promova, A. S., Astsaturov, I., Sererebriiskii, I. G., Dunbrack, R. L. & Golemis, E. A. Aurora A kinase (AURKA) in normal and pathological cell division. Cell. Mol. Life Sci. 70, 661–687 (2013).
13. Burgess, S. G. et al. Mitotic spindle association of TACC3 requires Aurora-A-dependent stabilization of a cryptic α-helix. EMBO J. 37, e97902 (2018).
14. Levinson, N. M. The multifaceted allosteric regulation of Aurora kinase A. Biochem. J. 475, 2025–2042 (2018).
15. Dodson, C. A. & Bayliss, R. Activation of Aurora-A kinase by protein partner binding and phosphorylation are independent and synergistic. J. Biol. Chem. 287, 1150–1157 (2012).
16. Zorba, A. et al. Molecular mechanism of Aurora A kinase autophosphorylation and its allosteric activation by TPX2. eLife 3, e02667 (2014).
17. Booth, D. G., Hood, F. E., Prior, I. A. & Royle, S. J. A TACC3/ch-TOG/ clathrin complex stabilises kinetochore fibres by inter-microtubule bridging: TACC3/ch-TOG/clathrin inter-microtubule bridges. EMBO J. 30, 906–919 (2011).
18. Floyd, S., Pines, J. & Lindon, C. APC/C/Cdh1 targets Aurora kinase to control reorganization of the mitotic spindle at anaphase. Cell Biol. 18, 1649–1658 (2008).
19. Honda, K. et al. Degradation of human Aurora2 protein kinase by the anaphase-promoting complex-ubiquitin-proteasome pathway. Oncogene 19, 2812–2819 (2000).
20. Plotnikova, O. V. et al. Calmodulin activation of Aurora-A kinase (AURKA) is required during ciliary disassembly and in mitosis. MBio 23, 2658–2670 (2012).
21. Büchel, G. et al. Association with Aurora-A controls N-MYC-dependent promoter escape and pause release of RNA polymerase II during the cell cycle. Cell Rep. 21, 3483–3497 (2017).
22. Byram, A. K. et al. Mitotic regulators TPX2 and Aurora A protect DNA forks during replication stress by counteracting 53BP1 function. J. Cell Biol. 218, 422–432 (2019).
23. Bertolin, G. et al. Aurora kinase A localises to mitochondria to control organelle dynamics and energy production. Elife 7, e38111 (2018).
24. Abdelhake, A. et al. AURKA destruction is decoupled from its activity at mitotic exit but essential to suppress interphase activity. J. Cell Sci. 133, jcs24071 (2020).
25. Grant, R. et al. Constitutive regulation of mitochondrial morphology by Aurora A kinase depends on a predicted cryptic targeting sequence at the N-terminus. Open Biol. 8, 170272 (2018).
26. Sackett, K. L. et al. Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C. Nature 514, 646–649 (2014).
27. Courtois, T. et al. Aurora A kinase activity is required to maintain an active spindle assembly checkpoint during prometaphase. J. Cell Sci. 131, jcs191353 (2018).
28. Wysong, D. R., Chakravarty, A., Hou, K. & Ecsedy, J. A. The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents. Cell Cycle 8, 876–888 (2009).
29. Yu, F. et al. Aurora-A promotes the establishment of spindle assembly checkpoint by priming the Haspin-Aurora-B feedback loop in late G2 phase. Cell Discov. 3, 18049 (2017).
30. Brito, D. A. & Rieder, C. L. Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr. Biol. 16, 1194–1200 (2006).
31. Collin, P., Naschkechina, O., Walker, R. & Pines, J. The spindle assembly checkpoint works like a rheostat rather than a toggle switch. Nat. Cell Biol. 15, 1378–1385 (2013).
32. Littlepage, J. E. & Ruderman, J. V. Identification of a new APC/C recognition domain, the A box, which is required for the CDH1-dependent destruction of the kinase Aurora-A during mitotic exit. Genes Dev. 16, 2274–2285 (2002).
33. Crane, R. Requirements for the destruction of human Aurora-A. J. Cell Sci. 117, 5975–5983 (2004).
34. Lindon, C., Grant, R. & Min, M. Ubiquitin-mediated degradation of aurora kinases. Front. Oncol. 5, 307 (2015).
35. Salami, J. et al. Androgen receptor degradation by the proteolysis-targeting chimeric ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance. Commun. Biol. 1, 100 (2018).
36. Smith, B. E. et al. Differential PROTAC substrate specificity dictated by recruitment of recruited E3 ligase. Nat. Commun. 10, 131 (2019).
37. Bondeson, D. P. et al. Lessons in PROTAC design from selective degradation with a promiscuous warhead. Cell Chem. Biol. 25, 78–87 (2018).
38. Joukov, V., Walter, J. C. & De Nicolo, A. The Cep192-organized Aurora A-Plk1 cascade is essential for centrosome cycle and bipolar spindle assembly. *Mol. Cell* **55**, 578–591 (2014).
39. Gallini, S. et al. NuMA phosphorylation by Aurora-A orchestrates spindle orientation. *Curr. Biol.* **26**, 458–469 (2016).
40. Lake, E. W. et al. Quantitative conformational profiling of kinase inhibitors reveals origins of selectivity for Aurora kinase activation states. *Proc. Natl Acad. Sci. USA* **115**, E11894–E11903 (2018).
41. Bibby, R. A. et al. A cancer-associated Aurora A mutant is mislocalized and misregulated due to loss of interaction with TPX2. *J. Biol. Chem.* **284**, 33177–33184 (2009).
42. Giet, R. & Prigent, C. The non-catalytic domain of the Xenopus laevis auroraA kinase localises the protein to the centrosome. *J. Cell Sci.* **114**, 2095–2104 (2001).
43. Hirota, T. et al. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. *Cell* **114**, 585–598 (2003).
44. Plotnikova, O. V., Pugacheva, E. N., Dunbrack, R. L. & Golemis, E. A. Rapid calcium-dependent activation of Aurora-A kinase. *Nat. Commun.* **1**, 64 (2010).
45. Bai, M. et al. Two newly identified sites in the N-terminal regulatory domain of Aurora-A are essential for auto-inhibition. *Biotechnol. Lett.* **36**, 1595–1604 (2014).
46. Chamberlain, P. P. & Hamann, L. G. Development of targeted protein degradation therapeutics. *Nat. Chem. Biol.* **15**, 937–944 (2019).
47. Lu, Y., Lee, B., King, R. W., Finley, D. & Kirschner, M. W. Substrate degradation by the proteasome: a single-molecule kinetic analysis. *Science* **348**, 1250834 (2015).
48. Kim, K. et al. Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera. *Sci. Rep.* **9**, 19654 (2019).
49. Baylis, K., Sardon, T., Vernos, I. & Conti, E. Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. *Mol. Cell* **12**, 851–862 (2003).
50. Raff, E. F. et al. A dynamic mechanism for allosteric activation of Aurora kinase A by activation loop phosphorylation. *eLife* **7**, e32766 (2018).
51. Floyd, S. et al. Spatiotemporal organization of Aurora-B by APC/Cdc1l1 after mitosis coordinates cell spreading through FHOD1. *J. Cell. Sci.* **126**, 2845–2856 (2013).
52. Zhu, F. et al. The mammalian SPD-2 ortholog Cep192 regulates centrosome biogenesis. *Curr. Biol.* **18**, 136–141 (2008).
53. Edelstein, A. D. et al. Advanced methods of microscope control using μManager software. *J. Biol. Methods* **1**, 10 (2014).
54. Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. *Nat. Methods* **9**, 676–682 (2012).
55. Peng, J.-Y. et al. Automatic morphological subtyping reveals new roles of caspases in mitochondrial dynamics. *PLoS Comput. Biol.* **7**, e1002212 (2011).

**Acknowledgements**

We thank Fanni Gergely and Laurent Pelletier for antibodies, Ian Storer, Zhongqian Sun and Zhengxi Li for Cpd A and D resynthesis and for design and synthesis of Cpd DX. Andreas Hock made valuable comments on the manuscript. R.W. was supported by BBSRC-DTP, C.A. by a AstraZeneca-funded studentship and A.A. by a Yousef Jameel Scholarship from the Cambridge International Trust. Work in C.L.’s lab is funded by BBSRC (BB/R004137/1).

**Author contributions**

Study conceived and designed by C.L. and K.R. T.R. synthesized compounds used. Experimental work was carried out and analysed by R.W., C.A., A.A., A.F. Manuscript written by C.L., R.W., C.A., and revised by K.R., I.M., R.W., and C.A.

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Supplementary information**

The online version contains supplementary material available at https://doi.org/10.1038/s42003-021-02158-2.

**Correspondence** and requests for materials should be addressed to C.L.

**Reprints and permission information** is available at http://www.nature.com/reprints

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.